His main scientific interest is the molecular biology of cell signal transduction, in relation to lung carcinogenesis. He first worked in the field of Rho proteins and their involvement in cytoskeleton control, cell adhesion and motility, before moving on p53 mutations molecular diagnosis in lung cancer. More recently, he focused his basic research work on the RASSF1A pathway alterations in lung cancer. In parallel, he has been investigator of more than 50 phase I, II and III clinical trials during the last decade, in the field of lung cancer and mesothelioma.
Dr. G. Zalcman authored or co-authored more than 150 peer-reviewed publications
Since the 1st Sept. 2015, Dr. G. Zalcman is the Head of the Thoracic Oncology Department of Bichat Hospital, in Paris (Paris-Diderot University) and joined the U830 INSERM laboratory, « Genetics & Biology of cancers » at the Research Centre of Curie Institute.